**Methods** One thousand four hundred and six consecutive patients, who underwent CAG at Daxing hospital from February 2007 through to March 2010 were enrolled. Of the 1406 patients, 351 patients were diagnosed as type 2 diabetes mellitus, 1055 patients were diagnosed as non-diabetic mellitus after admission to hospital. By evaluating the coronary angiogram, the patients were not diagnosed to have coronary heart disease (CHD) with less than 50% diameter stenosis of coronary artery; CHD was defined as narrowing of the appropriate lumen of $\geq 50\%$; the procedure of percutaneous coronary intervention (PCI) were performed in the patients with more than or equal to 70% stenosis; the coronary aortic bypass graft (CABG) surgery had been proposed in patients with left main coronary artery lesions, left main equivalent, diffuse triple coronary artery lesions, two- vessel disease with significant proximal left anterior descending CAD, however the determinations of the therapeutic choice were combined with clinical data.

**Results** The baseline characteristics of patients with and without diabetics undergone coronary angiography were as following. The age was significantly older in patients with diabetes than without diabetes ($62.02 \pm 9.70$ vs $57.76 \pm 9.94$, $p<0.0005$). More female patients in the diabetes group than non-diabetes group (45.30% vs 35.58%, $p<0.0005$). The morbidity rate of UAP (64.96% and 49.86%, $p<0.0005$), and Hypertension (50.06% and 69.57%, $p<0.0005$) were significantly higher in patients with diabetes than without diabetes. By evaluating the coronary angiogram, more patients were diagnosed to CHD in the diabetes group than non-diabetes group (45.30% vs 31.91%, $p<0.0005$).

**Conclusion** The morbidity rate of coronary heart disease among patients with type 2 diabetes is greater than non-diabetes, patients with type 2 diabetes have a significantly higher rate of coronary artery bypass grafting which had been proposed.

**Conclusions** Our study showed patients with CTO and diabetes have a tendency of poor prognosis after PCI, which may be largely due to the complicated renal impairment.

**Background** Percutaneous coronary intervention (PCI)-induced myocardial damage is a major cause of late cardiovascular events. Treatment with atorvastatin before PCI can reduce myocardial damage during the peri-PCI period. Objectives: To compare the safety and myocardial effects of different atorvastatin loading doses and dosing frequency before PCI in non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients.

**Methods** 80 NSTE-ACS patients were randomly divided into four groups (20 patients/group). The control group was given 40 mg atorvastatin each November. The three loading dose groups were treated as in the control group, but were given 80 mg atorvastatin 12 h before PCI (low-load group) in combination with 40 mg atorvastatin 2–4 h before PCI (mid-load group) or 60 mg atorvastatin 2–4 h before PCI (high-load group). All patients underwent PCI within 48–72 h of admission, and received 40 mg atorvastatin for at least 1 month after PCI. Changes in myocardial markers and high sensitive C-reactive protein (hs-CRP) were analysed. Patients were followed-up for 30 days to monitor the incidence of major adverse cardiac events (MACE).

**Results** No deaths or revascularisations were recorded. The incidences of MACE differed significantly between the four groups (40%, 25%, 10% and 0%, respectively, $p<0.05$). The incidence of MACE and cardiac troponin I (cTnI) level above the normal range, and post-PCI increases in creatine kinase-myo-cardial band (CK-MB) and hs-CRP were significantly higher in the control group than in the high-load group (all, $p<0.007$). The post-PCI cTnI and CK-MB levels were similar to the pre-PCI levels in the high-load group, but increased significantly in the control and low-load groups. The magnitude of the hs-CRP level increased was significantly lower in the high-load group, but increased significantly in the control and low-load groups. The post-PCI alanine aminotransferase levels in all four groups were significantly higher than the pre-PCI levels, but were within normal ranges. No myalgia or myasthenia was observed.

**Conclusion** This study shows that short-term atorvastatin loading before PCI was well tolerated had beneficial myocardial effects in patients with NSTE-ACS.

**Aims** To determine the effects of percutaneous coronary intervention (PCI) on cardiac perfusion, cardiac function and quality of life in patients with chronic total occlusion (CTO) lesion in left anterior descending (LAD) coronary artery.